IL98425A - Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline - Google Patents

Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline

Info

Publication number: IL98425A
Authority: IL; Israel
Prior art keywords: composition; quinoline; carboxylic acid; combination; carbon atoms
Prior art date: 1990-06-11

Application number

IL9842591A

Other languages

English (en)

Hebrew (he)

Original Assignee

Du Pont Merck Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-11

Filing date

1991-06-10

Publication date

1995-06-29

1991-06-10 Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma

1995-06-29 Publication of IL98425A publication Critical patent/IL98425A/en

Links

238000002054 transplantation Methods 0.000 title claims abstract description 17
210000000056 organ Anatomy 0.000 title claims description 12
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
238000011282 treatment Methods 0.000 title abstract description 12
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
VQMSRUREDGBWKT-UHFFFAOYSA-N quinoline-4-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=CC=NC2=C1 VQMSRUREDGBWKT-UHFFFAOYSA-N 0.000 claims abstract description 30
239000003018 immunosuppressive agent Substances 0.000 claims abstract description 20
229940125721 immunosuppressive agent Drugs 0.000 claims abstract description 18
208000024908 graft versus host disease Diseases 0.000 claims abstract description 7
PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 claims abstract description 4
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 3
208000037976 chronic inflammation Diseases 0.000 claims abstract description 3
208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 31
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 30
108010036949 Cyclosporine Proteins 0.000 claims description 30
229930105110 Cyclosporin A Natural products 0.000 claims description 29
229960001265 ciclosporin Drugs 0.000 claims description 29
125000000217 alkyl group Chemical group 0.000 claims description 26
-1 4-quinoline-carboxylic acid compound Chemical class 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 22
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 18
229960002170 azathioprine Drugs 0.000 claims description 17
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 13
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
229910052708 sodium Inorganic materials 0.000 claims description 12
239000011734 sodium Substances 0.000 claims description 12
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
229910052736 halogen Inorganic materials 0.000 claims description 11
150000002367 halogens Chemical class 0.000 claims description 11
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 7
229960004618 prednisone Drugs 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
208000009329 Graft vs Host Disease Diseases 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 6
229960000951 mycophenolic acid Drugs 0.000 claims description 6
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 5
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 4
125000004423 acyloxy group Chemical group 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims description 4
229960005249 misoprostol Drugs 0.000 claims description 4
229950000844 mizoribine Drugs 0.000 claims description 4
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
229960002930 sirolimus Drugs 0.000 claims description 4
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
108010002350 Interleukin-2 Proteins 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 3
102000005962 receptors Human genes 0.000 claims description 3
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
229910052740 iodine Inorganic materials 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
229910052799 carbon Inorganic materials 0.000 claims 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
229910052700 potassium Inorganic materials 0.000 claims 1
239000011591 potassium Substances 0.000 claims 1
229960003975 potassium Drugs 0.000 claims 1
235000007686 potassium Nutrition 0.000 claims 1
230000002265 prevention Effects 0.000 abstract description 7
230000001629 suppression Effects 0.000 description 14
239000003795 chemical substances by application Substances 0.000 description 13
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 11
239000004480 active ingredient Substances 0.000 description 8
230000001506 immunosuppresive effect Effects 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
208000010247 contact dermatitis Diseases 0.000 description 7
239000003246 corticosteroid Substances 0.000 description 6
229960001334 corticosteroids Drugs 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
YTRMTPPVNRALON-UHFFFAOYSA-N 2-phenyl-4-quinolinecarboxylic acid Chemical class N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=CC=C1 YTRMTPPVNRALON-UHFFFAOYSA-N 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000028993 immune response Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
230000002195 synergetic effect Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
206010014025 Ear swelling Diseases 0.000 description 4
206010029155 Nephropathy toxic Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
231100000304 hepatotoxicity Toxicity 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
231100000417 nephrotoxicity Toxicity 0.000 description 4
230000007694 nephrotoxicity Effects 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 3
238000011360 adjunctive therapy Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 2
108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 2
102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000008102 immune modulation Effects 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
238000002650 immunosuppressive therapy Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000004006 olive oil Substances 0.000 description 2
235000008390 olive oil Nutrition 0.000 description 2
230000004044 response Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
WYKKHJQZENLZID-UHFFFAOYSA-N 6-fluoro-3-methyl-2-(4-phenylphenyl)quinoline-4-carboxylic acid Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1 WYKKHJQZENLZID-UHFFFAOYSA-N 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101100225059 Mus musculus Ear3 gene Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
GDVNLLJNADMLLR-BBRMVZONSA-N Spergualin Chemical class NCCCNCCCCNC(=O)[C@H](O)NC(=O)C[C@@H](O)CCCCN=C(N)N GDVNLLJNADMLLR-BBRMVZONSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000009471 action Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000037189 immune system physiology Effects 0.000 description 1
229940073062 imuran Drugs 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
150000003165 prostaglandin E1 derivatives Chemical class 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000002719 pyrimidine nucleotide Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005951 type IV hypersensitivity Effects 0.000 description 1
208000027930 type IV hypersensitivity disease Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Transplantation (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compounds Of Unknown Constitution (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IL9842591A 1990-06-11 1991-06-10 Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline IL98425A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/535,672 US5204329A (en)	1990-06-11	1990-06-11	Treatment of organ transplantation rejection

Publications (1)

Publication Number	Publication Date
IL98425A true IL98425A (en)	1995-06-29

Family

ID=24135268

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9842591A IL98425A (en)	1990-06-11	1991-06-10	Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline

Country Status (14)

Country	Link
US (1)	US5204329A (fr)
EP (1)	EP0537191B1 (fr)
JP (1)	JPH05507697A (fr)
KR (1)	KR930700107A (fr)
AT (1)	ATE165511T1 (fr)
AU (1)	AU664354B2 (fr)
CA (1)	CA2085002A1 (fr)
DE (1)	DE69129332T2 (fr)
DK (1)	DK0537191T3 (fr)
ES (1)	ES2114888T3 (fr)
IE (1)	IE911962A1 (fr)
IL (1)	IL98425A (fr)
WO (1)	WO1991019498A1 (fr)
ZA (1)	ZA914456B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH06116151A (ja) *	1991-08-06	1994-04-26	Asahi Chem Ind Co Ltd	増殖性皮膚疾患治療用組成物
US6270766B1 (en)	1992-10-08	2001-08-07	The Kennedy Institute Of Rheumatology	Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US6770279B1 (en) *	1992-10-08	2004-08-03	The Kennedy Institute Of Rheumatology	TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
US5409886A (en) *	1993-02-18	1995-04-25	Mitsui Toatsu Chemicals, Incorporated	3-pyrroline-2-one derivatives and herbicidal compositions containing same
US6171585B1 (en)	1993-05-14	2001-01-09	Cedars-Sinai Medical Center	IVIg immunosuppression in HLA-sensitized transplant recipients
US20020068057A1 (en) *	1994-03-10	2002-06-06	Marc Feldmann	Treatment of autoimmune and inflammatory disorders
US5578609A (en) *	1994-03-25	1996-11-26	The Dupont Merck Pharmaceutical Company	2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
US5627193A (en) *	1995-02-09	1997-05-06	Mitsui Toatsu Chemicals, Inc.	Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
WO1997042953A1 (fr) *	1996-05-10	1997-11-20	Novartis Ag	Utilisation de brequinar et de derives contre le rejet chronique de greffes allogeniques et la xenotransplantation
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
US6376670B1 (en)	1997-06-19	2002-04-23	Sepracor Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
HUP0003364A3 (en)	1997-06-19	2002-03-28	Sepracor Inc Marlborough	Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) *	1997-06-19	2000-08-15	Sepracor, Inc.	Quinoline-indole antimicrobial agents, uses and compositions related thereto
UA65587C2 (en) *	1997-10-09	2004-04-15	Baker Norton Pharma	Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
WO1999038846A1 (fr) *	1998-01-30	1999-08-05	Procept, Inc.	Agents immunosuppresseurs
TW581681B (en) *	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
KR100312454B1 (ko) *	1998-03-27	2001-11-14	김용규	토토마이세틴을 생산하는 스트렙토마이세스 속 미생물 및 그로부터 생산된 토토마이세틴을 유효성분으로 함유하는 면역억제제
US7323471B1 (en)	1999-08-13	2008-01-29	Dor Biopharma, Inc.	Topical azathioprine for the treatment of oral autoimmune diseases
CN105916522A (zh)	2013-11-22	2016-08-31	建新公司	用于治疗神经变性疾病的新方法
WO2015120317A1 (fr) *	2014-02-07	2015-08-13	Neurocrine Biosciences, Inc.	Compositions pharmaceutiques comprenant un médicament antipsychotique et un inhibiteur de vmat2 et utilisations de celles-ci
US11406707B2 (en) *	2014-02-10	2022-08-09	H. Lee Moffitt Cancer Center And Research Institute, Inc.	STAT3 phosphorylation during graft-versus-host disease
LT3875459T (lt)	2015-10-30	2024-02-26	Neurocrine Biosciences, Inc.	Valbenazino dihidrochlorido druskos ir jų polimorfai
JP6869988B2 (ja)	2015-12-23	2021-05-12	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	（Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法
MY199695A (en)	2017-01-27	2023-11-18	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors
PT3684333T (pt)	2017-09-21	2025-05-08	Neurocrine Biosciences Inc	Formulações e composições de valbenazina de alta dosagem, métodos, e kits relacionados com as mesmas
KR20250070134A (ko)	2017-10-10	2025-05-20	뉴로크린 바이오사이언시즈 인코퍼레이티드	특정 vmat2 억제제의 투여 방법
MX2020003421A (es)	2017-10-10	2020-07-20	Neurocrine Biosciences Inc	Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2021001017A (es)	2018-08-15	2021-04-19	Neurocrine Biosciences Inc	Metodos para la administracion de ciertos inhibidores de transportador vesicular de monoamina de proteinas transportadoras-2 (vmat2).
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR6592M (fr) *	1967-10-31	1968-12-30
GB1334705A (en) *	1970-06-19	1973-10-24	Ici Ltd	Pharmaceutical compositions containing kynurenic acid derivatives
CH576445A5 (fr) *	1972-03-10	1976-06-15	Ciba Geigy Ag
DE2449030A1 (de) *	1974-10-11	1976-05-20	Schering Ag	Neue pyridin-derivate
US4407803A (en) *	1981-08-17	1983-10-04	Abbott Laboratories	Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives
US4680299A (en) *	1984-04-30	1987-07-14	E.I. Du Pont De Nemours And Company	2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
FI75308C (sv) *	1985-01-25	1988-06-09	Ky Carlson Project Kb	Hydrostatiskt drivsystem.
US4625034A (en) *	1985-02-04	1986-11-25	Usv Pharmaceutical Corp.	1,2-Dihydro; 1,2,3,4-tetrahydro; 5,8 dihydro; and 5,6,7,8-tetrahydroquinoline derivatives
US4661499A (en) *	1985-06-18	1987-04-28	Merck Frosst Canada, Inc.	2-[(substituted)-phenoxymethyl]quinolines
GB8602372D0 (en) *	1986-01-31	1986-03-05	Sandoz Ltd	Organic compounds
US4851409A (en) *	1986-02-14	1989-07-25	Merck Frosst Canada Inc.	2-substituted quinoline dioic acids and pharmaceutical compositions
US4847381A (en) *	1987-08-31	1989-07-11	American Cyanamid Company	2-Phenyl-4-quinoline carboxylic acids
US4861783A (en) *	1988-04-26	1989-08-29	E. I. Du Pont De Nemours And Company	4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
US4968701A (en) *	1988-04-26	1990-11-06	E. I. Du Pont De Nemours And Company	4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents
DE3814504A1 (de) *	1988-04-29	1989-11-09	Bayer Ag	(alpha)-substituierte 4-(chinolin-2-yl-methoxy)phenylessigsaeuren und -ester, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

1990
- 1990-06-11 US US07/535,672 patent/US5204329A/en not_active Expired - Fee Related
1991
- 1991-06-05 EP EP91910880A patent/EP0537191B1/fr not_active Expired - Lifetime
- 1991-06-05 WO PCT/US1991/003788 patent/WO1991019498A1/fr not_active Ceased
- 1991-06-05 ES ES91910880T patent/ES2114888T3/es not_active Expired - Lifetime
- 1991-06-05 AT AT91910880T patent/ATE165511T1/de not_active IP Right Cessation
- 1991-06-05 DE DE69129332T patent/DE69129332T2/de not_active Expired - Fee Related
- 1991-06-05 CA CA002085002A patent/CA2085002A1/fr not_active Abandoned
- 1991-06-05 AU AU80873/91A patent/AU664354B2/en not_active Ceased
- 1991-06-05 KR KR1019920703177A patent/KR930700107A/ko not_active Ceased
- 1991-06-05 DK DK91910880T patent/DK0537191T3/da active
- 1991-06-05 JP JP91510655A patent/JPH05507697A/ja active Pending
- 1991-06-10 IE IE196291A patent/IE911962A1/en unknown
- 1991-06-10 IL IL9842591A patent/IL98425A/en not_active IP Right Cessation
- 1991-06-11 ZA ZA914456A patent/ZA914456B/xx unknown

Also Published As

Publication number	Publication date
EP0537191B1 (fr)	1998-04-29
DE69129332D1 (de)	1998-06-04
CA2085002A1 (fr)	1991-12-12
JPH05507697A (ja)	1993-11-04
WO1991019498A1 (fr)	1991-12-26
EP0537191A1 (fr)	1993-04-21
EP0537191A4 (en)	1993-08-11
ZA914456B (en)	1993-02-24
US5204329A (en)	1993-04-20
AU664354B2 (en)	1995-11-16
ES2114888T3 (es)	1998-06-16
AU8087391A (en)	1992-01-07
DK0537191T3 (da)	1998-10-07
DE69129332T2 (de)	1998-08-27
IE911962A1 (en)	1991-12-18
KR930700107A (ko)	1993-03-13
ATE165511T1 (de)	1998-05-15

Publication	Publication Date	Title
IL98425A (en)	1995-06-29	Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline
EP0533280B2 (fr)	2004-12-01	Nouvelle indication médicale pour les antagonistes des tachykinines
AU704955B2 (en)	1999-05-13	Use of CGMP-phosphodiesterase inhibitors to treat impotence
US5190753A (en)	1993-03-02	3-phenyl-5,6-dihydrobenziciacridine-7-carboxylic acids and related compounds as immunosuppressive agents
CN101848708B (zh)	2013-01-02	皮质类固醇用于制备治疗埃坡霉素或埃坡霉素衍生物诱导的腹泻的药物
US5190972A (en)	1993-03-02	Method of combatting cyclosporine organ toxicity with prostaglandin analogs
HK1011503A1 (en)	1999-07-09	Immunosuppressive compositions
CA2362918A1 (fr)	2000-09-14	Procedes et compositions pour le traitement de la dyserection
Kay	1994	Immunosuppressive agents in chronic severe asthma
EP3854402A1 (fr)	2021-07-28	Traitement ou prévention de rejet de greffe
Emre et al.	1990	Beneficial effect of thalidomide and ciclosporin combination in heterotopic cardiac transplantation in rats
CA2417677A1 (fr)	2003-01-27	Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre
KR100681626B1 (ko)	2007-02-09	과다 반응성 염증 질환 및 자가면역질환의 치료를 위한 15-디옥시스페르구알린의 용도
EP0372541A1 (fr)	1990-06-13	Procédé pour impartir l'immunosupression
US20060079513A1 (en)	2006-04-13	Methods and compositions including methscopolamine nitrate
CN102614180A (zh)	2012-08-01	伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
NL8700191A (nl)	1987-08-17	Immunosuppressieve middelen, farmaceutische preparaten die ze bevatten en het toepassen van deze middelen.
AU2004260624A1 (en)	2005-02-10	Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
CZ2001150A3 (cs)	2001-09-12	Lék pro léčbu psychóz nebo jiných neuropsychiatrických příznaků u pacientů s Alzheimerovou chorobou
JPS6116A (ja)	1986-01-06	有機化合物に関する改良
JP2800412B2 (ja)	1998-09-21	免疫抑制作用増強剤
CN112274511A (zh)	2021-01-29	用于治疗移植物抗宿主病的喹啉衍生物
US20010014676A1 (en)	2001-08-16	Immunosuppressive compositions
MXPA02007747A (es)	2002-10-23	Agente para el tratamiento del sindrome de sj°gren.
IE912825A1 (en)	1992-02-12	Immunosuppressive compositions

Legal Events

Date	Code	Title	Description
1997-09-30	KB	Patent renewed
2002-02-10	MM9K	Patent not in force due to non-payment of renewal fees